Caplin Point Laboratories advances 9.93% to Rs 424.4 at 15:17 IST on the BSE after the company said its subsidiary received the establishment inspection report from the US drug regulator.
The announcement was made during market hours today, 25 July 2019.
Meanwhile, the S&P BSE Sensex was down by 26.05 points or 0.07% to 37,821.21.
On the BSE, 11000 shares were traded in the counter so far compared with average daily volumes of 2615 shares in the past two weeks. The stock had hit a high of Rs436 and a low of Rs 385 so far during the day. It hit a 52-week high of Rs 535 on 10 September 2018 and a 52-week low of Rs 304.75on 29 January 2019.
The company announced that its wholly-owned subsidiary, Caplin Steriles, received the Establishment Inspection Report (EIR) from USFDA for the recently concluded inspection in June 2019. This was the third successful USFDA audit at the plant since 2016.
On consolidated basis, Caplin Point Laboratories' net profit increased 41% to Rs 49.86 crore on a 30.6% rise in net sales to Rs 187.34 crore in Q4 March 2019 over Q4 March 2018.
Caplin Point Laboratories is a pharmaceutical company, catering predominantly to emerging markets of Latin America and Africa.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
